





## Introduction

- US-EPA and Unilever are collaborating to develop new, more efficient approaches for chemical safety assessment.
- In this case study, we combined *in vivo*, *in vitro* and toxicokinetics data for the purpose of assessing chemical safety using read-across.
- Read-across can be used to fill data gaps in chemical safety assessments.
- The read-across workflow comprises several steps starting with the identification and evaluation of source analogs.
- Analog evaluation includes assessing the physicochemical and mechanistic similarity of source analogs.
- Different data inputs (*in vivo*, *in vitro*, *in silico*) characterize the similarity context to justify read-across predictions.
- The main goal of this study was to construct a quantitative read-across prediction of point of departure (POD) using caffeine as a target chemical.**
- To provide a more complete profile of caffeine, we have predicted receptor mediated bioactivity, genotoxicity and possible metabolites.
- Finally, we performed an *in vitro* to *in vivo* extrapolation (IVIVE) directly on caffeine using *in vitro* assay activity ( $AC_{50}$ ) and high-throughput Toxicokinetics (HTTK) data to derive intended bioactivity dose.

## Methods




**Scheme-1:** Read-across POD prediction




**Scheme-2:** IVIVE margin of safety prediction

## Results: scheme 1


Thirteen analogs were identified for caffeine based on structural similarity. Among those only three were found to have ToxCast *in vitro* bioassay data.



**Figure 1:** Structures of target (caffeine) and its identified analogs (paraxanthine, theobromine and theophylline).



**Figure 2:** Analysis of *in vitro* assay data to identify biological similarity between the target and its analogs.



**Figure 3:** Predicted metabolites of caffeine in the *in vivo* rat TIMES# metabolism simulator show that the three analogs are likely metabolites, further supporting their use as read-across analogs. (Complete predicted metabolic pathway not shown).

\*Reference: Curr. Pharm. Des., 10, 2004, pp. 1273-1293

## Scheme 1: Read-across prediction of POD

**Table 1:** Prediction of LEL for caffeine: the most conservative LEL value among analogs was chosen as predicted LEL for caffeine. A cup of coffee is equivalent to a dose of 1-2 mg/kg/day.


	Target	Analog-1	Analog-2
	Caffeine	Theophylline	Theobromine
Sub-chronic toxicity (species = rat)	100 mg/kg/day	75 mg/kg/day	250 mg/kg/day
Chronic toxicity (species = rat)	49 mg/kg/day	7.5 mg/kg/day	250 mg/kg/day
<b>Predicted POD (species = rat)</b>	<b>7.5 mg/kg/day</b>		

Human equivalent dose (HED) = rat dose / 6.2  
HED = 1.2 mg/kg/day

## Results: scheme 2

**Scheme 2: IVIVE prediction of *in vivo* potency for caffeine for its intended target**

**Figure 4:** *In vitro* to *in vivo* extrapolation to predict human doses.



\*Reference: <http://healthstat.snu.ac.kr/CRAN/web/packages/httk/httk.pdf>

**Predicted margin of safety = 1.2 / 0.1 = 12**

## Supporting information for caffeine's toxicity profile

In addition to POD and human dose we have also predicted other possible toxicities of caffeine using TIMES model.

**Table 2:** Predictions for caffeine using TIMES Models that account for metabolism, compared with experimental data when available.

Source	Alert	Result	Source	Experimental Information
TIMES	<i>In vivo</i> Comet Genotoxicity	Positive	-	-
TIMES	<i>In vivo</i> liver Clastogenicity	Positive	HSDB	Not clastogenic in <i>in vivo</i> mouse model
TIMES	<i>In vivo</i> TGR Mutagenicity	Negative	-	-
TIMES	<i>In vivo</i> Micronucleus	Positive	CCRIS	Negative in <i>in vivo</i> micronucleus test in mouse
TIMES	<i>In vitro</i> Ames Mutagenicity	Negative	-	-
TIMES	<i>In vitro</i> Chromosomal aberration	Positive	HSDB	Did not increase CA in <i>in vitro</i> CHO assay
TIMES	Estrogen binding affinity s9 activated	Inactive	-	-
TIMES	Skin sensitization with autoxidation	Non-sensitizer	-	-

## Conclusions

- The study demonstrates that the point of departure (POD) for caffeine can be predicted by quantitative read-across using physicochemical, *in vitro* and *in vivo* data.
- Caffeine and its 2 analogs were active in three assays related to blockade of adenosine receptor A1 and A2a, demonstrating mechanistic similarity among target and analogs. The analogs are also direct metabolites of caffeine.
- The *in vitro* assay concentration at which target compound was blocking adenosine receptor was chosen as input to predict the human bioactivity dose prediction, combined with HTTK data.
- This IVIVE study yielded a dose for target bioactivity of 0.1 mg/kg/day, significantly lower than the *in vivo* read-across POD (1.2 mg/kg/day).
- The read-across prediction derived for caffeine provide a proof of principle of this approach for using structure, physicochemical and *in vitro* data to help select read-across analogs.